Skip to content
Aminoscope
Head-to-head

Oral semaglutide vs Orforglipron

The two GLP-1s you can swallow. One is a peptide with food and water rules, the other a small molecule with none — and their records are not the same size.

By Julian RothResearch & dataUpdated November 2026

Short answer

On weight loss, oral semaglutide comes out ahead, with 15.1% at 68 weeks in OASIS 1 against 11.2% at 72 weeks in ATTAIN-1 for orforglipron. Those figures come from separate trials, not a head-to-head study. Both are FDA-approved. The table below compares their FDA status, route, headline human result and main safety signal side by side.

Oral semaglutide

Rybelsus, Wegovy pill

FDA-approved

The Oral semaglutide evidence review explains what has been studied. The first oral GLP-1 — approved for type-2 diabetes on the PIONEER program (as Rybelsus) and, since December 2025, for chronic weight management and cardiovascular risk reduction at a higher 25 mg dose (as the Wegovy pill).

Orforglipron

FDA-approved

The Orforglipron evidence review explains what has been studied. ~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. FDA-approved for weight management (Foundayo, 2026) — the type-2 diabetes indication is still under review.

Oral semaglutide vs Orforglipron: head to head

The evidence matrix shows the source behind each grade and the use that grade applies to. A grade for one use does not carry over to every claim about the same molecule.

FDA status / approved use

Oral semaglutide

Approved as Rybelsus for type 2 diabetes; an oral version was FDA-approved for weight loss in December 2025

Orforglipron

FDA-approved April 2026 as Foundayo for chronic weight management; diabetes indication still under review
Marketed for

Oral semaglutide

Type-2 diabetes, weight loss

Orforglipron

Weight loss, type-2 diabetes
Outcome areas

Oral semaglutide

Blood sugar / insulin sensitivity

Orforglipron

Weight loss / appetite; Blood sugar / insulin sensitivity
Evidence grade

Oral semaglutide

FDA-approved

Orforglipron

FDA-approved
How it works

Oral semaglutide

GLP-1 receptor agonist absorbed through the stomach with the help of the enhancer SNAC

Orforglipron

Small-molecule, non-peptide GLP-1 receptor agonist that survives digestion
Route and dosing

Oral semaglutide

Oral tablet, once daily (Wegovy pill label); maintenance 25 mg once daily

Orforglipron

Oral tablet, once daily (Foundayo label); maintenance 5.5 mg or higher once daily, by response and tolerability
Headline human result

Oral semaglutide

15.1% mean weight loss vs 2.4% on placebo at 68 weeks (OASIS 1, 50 mg daily)

Orforglipron

11.2% mean weight loss vs 2.1% on placebo at 72 weeks (ATTAIN-1, 36 mg daily)
Strongest evidence

Oral semaglutide

Orforglipron

Key safety signal

Oral semaglutide

Gastrointestinal side effects similar to other GLP-1 drugs; cardiovascular safety cleared in PIONEER 6

Orforglipron

Dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet
How it is obtained

Oral semaglutide

Prescription. Eligible manufacturer self-pay offers for Wegovy (oral pill): $149–$299 per 30 days; dose, refill timing and program terms apply. Introductory prices can differ and regular prices may be higher.Wegovy cost breakdown

Orforglipron

Prescription drug

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.

Our verdict

Both are FDA-approved, so the choice is about what each has actually proven. Oral semaglutide came through the PIONEER program for type-2 diabetes as Rybelsus and, since December 2025, is approved at 25 mg for chronic weight management and cardiovascular risk reduction as the Wegovy pill — the deeper record of the two. Orforglipron reported about 11% weight loss in ATTAIN-1 and was approved for weight management in 2026 as Foundayo, with its type-2 diabetes indication still under review; being a non-peptide small molecule, it carries no food or water timing rules. The two have not been compared head to head. If semaglutide is the choice, the CoreAge Rx review shows compounded semaglutide starting at $79 a month, with the full quote still to confirm.

Oral semaglutide fits if

You want the oral GLP-1 with the longer record, including cardiovascular risk reduction, and the dosing rules are manageable for you.

Orforglipron fits if

The dosing rules are the obstacle, and a daily tablet with no food or water timing is worth a shallower evidence record.

Oral semaglutide vs Orforglipron: common questions

Are oral semaglutide and orforglipron both FDA-approved?
Yes. Oral semaglutide is approved as Rybelsus for type 2 diabetes; an oral version was FDA-approved for weight loss in December 2025. Orforglipron was FDA-approved in April 2026 as Foundayo for chronic weight management; diabetes indication still under review.
Which has stronger human evidence, oral semaglutide or orforglipron?
Neither clearly. Both have approval-level evidence. The key source for oral semaglutide is PIONEER 1, JAMA 2019; for orforglipron, it is ATTAIN-1, NEJM 2025.
What are the main safety concerns with oral semaglutide and orforglipron?
For oral semaglutide, watch for gastrointestinal side effects similar to other GLP-1 drugs; cardiovascular safety cleared in PIONEER 6. For orforglipron, watch for dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet.

Key studies behind each

Oral semaglutide

  1. Aroda VR, Rosenstock J, Terauchi Y, et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. PubMed 31186300
  2. Pratley R, Amod A, Hoff ST, et al. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. PubMed 31186120
  3. Husain M, Birkenfeld AL, Donsmark M, et al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med. PubMed 31185157
  4. Knop FK, Aroda VR, do Vale RD, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. PubMed 37385278

Orforglipron

  1. Frias JP, Hsia S, Eyde S, et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. PubMed 37369232
  2. Wharton S, et al. (2025). Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with cardiometabolic improvements. Cardiovasc Diabetol. PubMed 40481478
  3. Rosenstock J, Hsia S, Nevarez Ruiz L, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. PubMed 40544435
  4. Wharton S, Aronne LJ, Stefanski A, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. PubMed 40960239

The full evidence reviews

Related comparisons